Table 1.
Baseline demographics and data
| Parameters | Average |
|---|---|
| Age ± SD (min max) (years) | 63.2 ± 11.4 (32–85) |
| Female, n (%) | 195 (91.1) |
| Female over 60 years old, n (%) | 131 (61.1) |
| BMI ± SD (min max) (kg/m2) | 21.3 ± 3.1 (12.3–30.0) |
| HbA1c (NGSP) (min max) (%) | 5.65 ± 0.5 (4.6–9.2) |
| DAS-ESR ± SD (min max) | 3.2 ± 1.1 (0.5–6.6) |
| HAQ ± SD (min max) | 0.8 ± 0.7 (0–2.9) |
| TSS ± SD (min max) | 122.6 ± 108.0 (0–443) |
| MTX dose ± SD (mg) (min max) | 5.6 ± 3.9 (0–14) |
| Steroid dose ± SD (mg) (min max) | 1.77 ± 2.62 (0–15) |
| bDMARD use, n (%) | 67 (31.3) |
| Bisphosphonate use, n (%) | 67(31.3) |
| Vitamin D use, n (%) | 80(37.3) |
| Observation period (min max) (years) | 2.3 (1.2–3.5) |
| Lumbar spine BMD ± SD (min max) | 86.2 ± 18.3 (45.8–151.0) |
| Total hip-BMD ± SD (min max) | 81.8 ± 14.3 (45.0–119.0) |
| Distal forearm-BMD ± SD (min max) | 82.3 ± 22.0 (34.0–140.0) |
| The annual lumbar spine-BMD change ± SD (min max) | − 0.14 ± 2.70 |
| The annual total hip-BMD change ± SD (min max) | − 0.46 ± 1.63 |
| The annual distal forearm-BMD change ± SD (min max) | − 1.15 ± 1.85 |
| RF ± SD (min max) (U/ml) | 86.0 ± 129.4 (0–812.8) |
| ACPA ± SD (min max) (U/ml) | 125.9 ± 113.5 (0–300) |
| CRP ± SD (min max) (mg/dl) | 0.66 ± 1.32 (0–11.7) |
| TRACP-5b ± SD (min max) (mU/dl) | 320.0 ± 149.0 (68–877) |
| Homocysteine ± SD (min max) (nmol/ml) | 9.7 ± 3.5 (3.2–28.0) |
| Uc-OC ± SD (ng/mL) (min max) | 4.8 ± 4.1 (0–23.3) |
| BAP ± SD (μg/L) (min max) | 15.6 ± 6.4 (5.8–43.6) |
| Urinary pentosidine ± SD(pg/ml)(min max) | 47.1 ± 25.9 (11.5–196.0) |
BMI body mass index, HbA1c NGSP Hemoglobin A1C National Glycohemoglobin Standardization Program, DAS28-ESR disease activity score in 28 joints-erythrocyte sedimentation rate, HAQ health assessment questionnaire, TSS total Sharp/van der Heijde score, MTX methotrexate, bDMARDs biological disease-modifying anti-rheumatic drugs, BMD bone mineral density (data was shown with young adult mean), RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, TRACP-5b tartrate-resistant acid phosphatase 5b, Uc-OC undercarboxylated osteocalcin, BAP bone-specific alkaline phosphatase